Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.
|Original language||English (US)|
|Number of pages||21|
|Journal||Obstetrics and Gynecology Clinics of North America|
|State||Published - Dec 1 2007|
ASJC Scopus subject areas
- Obstetrics and Gynecology